Modella AI and AstraZeneca link for cancer clinical development
Modella AI has signed a multi-year agreement with AstraZeneca to expedite AI-driven oncology clinical development. The partnership will give AstraZeneca…
All articles by
-
-
Biocon’s Denosumab biosimilars gain EU marketing authorisation
Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU). This approval from the…
-
Brii Biosciences and Joincare sign licence agreement for BRII-693
Brii Biosciences and the Joincare Pharmaceutical Group have signed a licence and technology transfer agreement for BRII-693, a new synthetic…
-
BioVersys and Shionogi agree to develop ansamycin leads
BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads from…
-
Ligand’s LNHC concludes merger with CHRO
Ligand Pharmaceuticals’ wholly owned subsidiary LNHC has concluded its merger with Channel Therapeutics’ CHRO Merger Sub, resulting in the formation…
-
FDA approves Dizal’s Zegfrovy to treat adults with NSCLC
Dizal has received US Food and Drug Administration (FDA) approval for Zegfrovy (sunvozertinib) to treat adults with locally advanced or…
-
Sanofi agrees to invest $25m in Adagene
Sanofi has agreed to invest up to $25m in Adagene, which will enable the latter to fund its research and…
-
Merck concludes SpringWorks acquisition for $3.4bn
Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving…
-
EC approves Jazz Pharmaceuticals’ Ziihera for biliary tract cancer
Jazz Pharmaceuticals has received conditional marketing authorisation from the European Commission (EC) for its new bispecific antibody, Ziihera (zanidatamab), for…
-
Sanofi’s riliprubart gains ODD status from Japan’s MHLW for CIDP
Sanofi's antibody riliprubart has received orphan drug designation (ODD) from Japan's Ministry of Health, Labour and Welfare (MHLW) for its…